Although the body weight significantly decreased in incretin based medicine group (80.0 kg to 78.1 kg, P < 0.01), the body weight did not change

in conventional treatments group (76.4 kg to 77.0 kg, P = 0.68). The cumulative normalization rates of serum ALT level significantly differed between the two groups (P = 0.04); 20.5%, and 35.1% at 250, and 500 days, respectively, in the incretin based medicine group and 15.8%, and 26.7% in the conventional treatments group. Multivariate analysis indicated that administration of incretin based medicine (OR 0.44, P < 0.01), existence of hypertension (OR 1.60, P = 0.048), and comorbidity with dyslipidemia (OR 1.64, P = 0.04) as independent factors which contributed to normalization of serum ALT level. Conclusions: Administration of incretin based medicine led not only selleck inhibitor good control

of type 2 DM but also reduction of body weight, and rapid improvement of liver inflammation. Disclosures: The following people have nothing to disclose: Takamasa Ohki, Isogawa Akihiro, Mari Yamagami, Tomoharu Yamada, Koki Sato, Yasuhide Yamamoto, Michiharu Seki, Nobuo Toda, Kazumi Tagawa BACKGROUND: Recurrence of non-alcoholic steatohepatitis (NASH) in up to 33% of the liver transplant (LT) recipients has been reported (Bhagat et al 2009). It is not known whether steroid free immunosuppression reduces the risk of NASH after liver transplantation. AIM: We aimed to determine the prevalence of NASH post- this website transplant in a cohort of patients with NASH cirrhosis and alcoholic cirrhosis (ETOH) who received a steroid free immunosuppression regimen based on one year protocol liver biopsy,

and determine risk factors for recurrence and outcomes for these patients. METHODS: We performed a retrospective review for all patients who underwent LT for NASH or ETOH who had protocol liver biopsy at one year follow up at our center from April 2006 to April 2012. Comparison was made between ETOH and NASH groups as well as those who developed steatohepatitis (SH group) and those who did not develop steatohepatitis (non-SH group). RESULTS: The study included 40 recipients (M/F: 20/20) in the NASH group and 47(M/F: 40/7) in the ETOH group. Recurrence/development of NASH in recipients of LT with cirrhosis secondary to NASH is significantly AZD9291 in vitro higher compared to recipients secondary to ETOH [16 of 40(40%) vs.8 of 47(17%); P= 0.017]. Multivariate analysis failed to identify any single predictive variable for predicting recurrence/development of steatohepatitis in both NASH and ETOH groups. Atherosclerotic cardiovascular events, defined as acute myocardial infraction, cerebrovascular accident, need for percutaneous coronary intervention and coronary artery bypass graft was noted in six recipients, 5(12.5%) from the NASH group, and 1(2.1%) from the ETOH group (P=0.09). Presence of steatohepatitis did not predict cardiovascular events (R=-0.68, P=0.54, OR 0.50) or death (R=0.73, P=0.37, OR 0.